Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent (EP3 433 269) by the European Patent Office protecting its PD1-41BB costimulatory switch protein (CSP) technology. Medigene’s PD1-41BB CSP was developed by its partner Helmholtz Munich and is exclusively licensed to Medigene.

“We are delighted to have been granted the European Patent for our PD1-41BB CSP, one of the key technologies of Medigene’s End-to-End (E2E) Platform. This complements our PD1-41BB IP-portfolio with similar patents already granted in the United States, China and Japan, and strengthens our patent portfolio worldwide,” said Selwyn Ho, CEO at Medigene AG. “At Medigene, we are committed to creating best-in-class, differentiated T cell receptor engineered T cells (TCR-T) therapies optimized for safety, efficacy and durability.The grant of this European patent in combination with the expansion of our exclusive license for the PD1-41BB CSP to be used in all cell types beyond TCR-T therapies validates our approach to continuously innovate to address the unmet need of patients with solid tumors.”

Medigene constantly extends and strengthens its patent portfolio with new technologies and expands existing patents into additional jurisdictions. The Company maintains over 20 different patent families worldwide covering applications protecting Medigene’s 3S (specific, sensitive and potentially safer) TCRs as well as the armoring and enhancement technologies of its E2E Platform.